(This is an excerpt from the subscriber-only DP Weekly Wrap for Friday) On Friday, the Biotechnology ETF (IBB) 20-day EMA crossed down through the 50-day EMA (Dark Cross) and above the 200-day EMA, generating an IT Trend Model NEUTRAL Signal. IBB recently switched to a BUY Signal on Friday November 8, and we said at the time, “IBB is approaching the top of a four-month trading range (resistance), so this BUY Signal doesn’t look very juicy at this time.” This emphasizes why we consider Trend Model signals to be information flags, not action commands. Always check the chart. Part of the reason Biotechs fell apart was the nomination of Robert F. Kennedy Jr. to the Health and Human Services department. He is known to be anti-COVID vaccines and just generally not a fan of chemicals for the body. This doesn’t necessarily bode well for this industry. Participation has been plummeting…
There’s no denying the strength that the mega-cap growth names have exerted on the equity markets in 2024. With their…
As the cybersecurity landscape continues to evolve with increasing digital threats, Zscaler, Inc. (ZS) stands out as a new…
In this StockCharts TV video, Mary Ellen reveals what took place last week and how the markets closed. She also…
Should you buy calls/puts? Should you write covered calls? Or should you trade bull/bear vertical spreads? That’s a lot…
Now that Q4 historical bullishness has kicked in, it’s time to allow the bears to go into hibernation, while…
With cryptocurrencies evolving from speculative assets to a global economic force, investors face a critical question: how can you…